Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Bevacizumab plus chemotherapy vs chemotherapy alone

Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer

Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 1.44 [1.16, 1.79]
1 study · 439 participants
Moderate

Bevacizumab plus chemotherapy vs chemotherapy alone

Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer

Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 5 [1.11, 22.56]
1 study · 440 participants
Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer

Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 4.5 [1.55, 13.08]
1 study · 440 participants
Moderate